Itraconazol Focus Care

Itraconazole, the active ingredient in Itraconazol Focus Care, is an azole antifungal presented as an oral formulation for systemic use. It is employed to treat a range of serious fungal infections, including systemic mycoses, blastomycosis, histoplasmosis, aspergillosis and candidiasis in adult patients.

GNH USA supplies Itraconazol Focus Care as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Itraconazol Focus Care is indicated for several invasive fungal infections, targeting organisms that cause systemic disease.

Systemic mycoses: effective in treating deep‑tissue fungal infections caused by susceptible species. Blastomycosis: used to eradicate Blastomyces dermatitidis infection. Histoplasmosis: helps clear Histoplasma capsulatum infection. Aspergillosis: employed in managing invasive Aspergillus infections. Candidiasis: treats severe Candida infections, including candidemia.

Itraconazole may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea - Vomiting - Abdominal pain - Headache - Rash - Elevated liver enzymes

Serious or Rare Side Effects: - Hepatotoxicity, including severe hepatitis - Severe skin reactions such as Stevens‑Johnson syndrome - Congestive heart failure exacerbation - Visual disturbances or blurred vision - QT interval prolongation and cardiac arrhythmias - Anaphylactic or severe allergic reactions

When prescribing Itraconazol Focus Care, clinicians should observe several precautionary measures to minimise risk.

- Liver function monitoring: assess baseline hepatic enzymes and repeat periodically. - Drug interaction vigilance: review concomitant medications that affect CYP3A4. - Hypersensitivity caution: avoid in patients with known allergy to itraconazole or other azoles. - Cardiac risk assessment: use cautiously in patients with existing heart failure. - Pregnancy and lactation: prescribe only if benefits outweigh potential risks. - Store below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Itraconazole interacts with several medicines through CYP3A4 inhibition or induction, requiring careful management.

Major Interactions (Avoid): - Rifampin, carbamazepine, phenytoin, or other strong CYP3A inducers: may markedly reduce itraconazole exposure. - Ketoconazole or other azole antifungals: can lead to excessive plasma concentrations. - HIV protease inhibitors such as ritonavir: increase risk of toxicity. - Certain statins (e.g., simvastatin, lovastatin): heightened risk of myopathy. - Oral contraceptives: may reduce contraceptive effectiveness.

Moderate Interactions (Monitor Closely): - Warfarin: itraconazole may enhance anticoagulant effect, requiring INR monitoring. - Macrolide antibiotics (e.g., erythromycin, clarithromycin): may increase itraconazole levels. - Calcium channel blockers (e.g., verapamil, diltiazem): potential for increased plasma concentrations. - Digoxin: possible increase in serum levels. - Antidepressants metabolised by CYP3A4 (e.g., sertraline): monitor for adverse effects.